225 related articles for article (PubMed ID: 26763448)
1. Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB.
Georgiadis C; Syed F; Petrova A; Abdul-Wahab A; Lwin SM; Farzaneh F; Chan L; Ghani S; Fleck RA; Glover L; McMillan JR; Chen M; Thrasher AJ; McGrath JA; Di WL; Qasim W
J Invest Dermatol; 2016 Jan; 136(1):284-92. PubMed ID: 26763448
[TBL] [Abstract][Full Text] [Related]
2. Collagen VII Expression Is Required in Both Keratinocytes and Fibroblasts for Anchoring Fibril Formation in Bilayer Engineered Skin Substitutes.
Supp DM; Hahn JM; Combs KA; McFarland KL; Schwentker A; Boissy RE; Boyce ST; Powell HM; Lucky AW
Cell Transplant; 2019; 28(9-10):1242-1256. PubMed ID: 31271052
[TBL] [Abstract][Full Text] [Related]
3. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.
Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A
J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967
[TBL] [Abstract][Full Text] [Related]
4. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.
Chen M; Kasahara N; Keene DR; Chan L; Hoeffler WK; Finlay D; Barcova M; Cannon PM; Mazurek C; Woodley DT
Nat Genet; 2002 Dec; 32(4):670-5. PubMed ID: 12426566
[TBL] [Abstract][Full Text] [Related]
5. Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.
Berthault C; Gaucher S; Gouin O; Schmitt A; Chen M; Woodley D; Titeux M; Hovnanian A; Izmiryan A
J Invest Dermatol; 2024 Jun; 144(6):1322-1333.e13. PubMed ID: 38043638
[TBL] [Abstract][Full Text] [Related]
6. Human Mesenchymal Stromal Cells Engineered to Express Collagen VII Can Restore Anchoring Fibrils in Recessive Dystrophic Epidermolysis Bullosa Skin Graft Chimeras.
Petrova A; Georgiadis C; Fleck RA; Allison L; McGrath JA; Dazzi F; Di WL; Qasim W
J Invest Dermatol; 2020 Jan; 140(1):121-131.e6. PubMed ID: 31326396
[TBL] [Abstract][Full Text] [Related]
7. Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo.
Woodley DT; Keene DR; Atha T; Huang Y; Ram R; Kasahara N; Chen M
Mol Ther; 2004 Aug; 10(2):318-26. PubMed ID: 15294178
[TBL] [Abstract][Full Text] [Related]
8. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa.
Gache Y; Baldeschi C; Del Rio M; Gagnoux-Palacios L; Larcher F; Lacour JP; Meneguzzi G
Hum Gene Ther; 2004 Oct; 15(10):921-33. PubMed ID: 15585108
[TBL] [Abstract][Full Text] [Related]
9. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
[TBL] [Abstract][Full Text] [Related]
10. SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa.
Titeux M; Pendaries V; Zanta-Boussif MA; Décha A; Pironon N; Tonasso L; Mejia JE; Brice A; Danos O; Hovnanian A
Mol Ther; 2010 Aug; 18(8):1509-18. PubMed ID: 20485266
[TBL] [Abstract][Full Text] [Related]
11. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa.
Lwin SM; Syed F; Di WL; Kadiyirire T; Liu L; Guy A; Petrova A; Abdul-Wahab A; Reid F; Phillips R; Elstad M; Georgiadis C; Aristodemou S; Lovell PA; McMillan JR; Mee J; Miskinyte S; Titeux M; Ozoemena L; Pramanik R; Serrano S; Rowles R; Maurin C; Orrin E; Martinez-Queipo M; Rashidghamat E; Tziotzios C; Onoufriadis A; Chen M; Chan L; Farzaneh F; Del Rio M; Tolar J; Bauer JW; Larcher F; Antoniou MN; Hovnanian A; Thrasher AJ; Mellerio JE; Qasim W; McGrath JA
JCI Insight; 2019 Jun; 4(11):. PubMed ID: 31167965
[TBL] [Abstract][Full Text] [Related]
12. Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes.
Latella MC; Cocchiarella F; De Rosa L; Turchiano G; Gonçalves MAFV; Larcher F; De Luca M; Recchia A
J Invest Dermatol; 2017 Apr; 137(4):836-844. PubMed ID: 28027893
[TBL] [Abstract][Full Text] [Related]
13. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.
Wong T; Gammon L; Liu L; Mellerio JE; Dopping-Hepenstal PJ; Pacy J; Elia G; Jeffery R; Leigh IM; Navsaria H; McGrath JA
J Invest Dermatol; 2008 Sep; 128(9):2179-89. PubMed ID: 18385758
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa.
Hong SA; Kim SE; Lee AY; Hwang GH; Kim JH; Iwata H; Kim SC; Bae S; Lee SE
Mol Ther; 2022 Aug; 30(8):2664-2679. PubMed ID: 35690907
[TBL] [Abstract][Full Text] [Related]
15. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone.
Woodley DT; Krueger GG; Jorgensen CM; Fairley JA; Atha T; Huang Y; Chan L; Keene DR; Chen M
J Invest Dermatol; 2003 Nov; 121(5):1021-8. PubMed ID: 14708601
[TBL] [Abstract][Full Text] [Related]
16. Keratinocyte-/fibroblast-targeted rescue of Col7a1-disrupted mice and generation of an exact dystrophic epidermolysis bullosa model using a human COL7A1 mutation.
Ito K; Sawamura D; Goto M; Nakamura H; Nishie W; Sakai K; Natsuga K; Shinkuma S; Shibaki A; Uitto J; Denton CP; Nakajima O; Akiyama M; Shimizu H
Am J Pathol; 2009 Dec; 175(6):2508-17. PubMed ID: 19893033
[TBL] [Abstract][Full Text] [Related]
17. Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In Vivo RDEB Model.
Turczynski S; Titeux M; Tonasso L; Décha A; Ishida-Yamamoto A; Hovnanian A
J Invest Dermatol; 2016 Dec; 136(12):2387-2395. PubMed ID: 27498345
[TBL] [Abstract][Full Text] [Related]
18. Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa.
Cogan J; Weinstein J; Wang X; Hou Y; Martin S; South AP; Woodley DT; Chen M
Mol Ther; 2014 Oct; 22(10):1741-52. PubMed ID: 25155989
[TBL] [Abstract][Full Text] [Related]
19. Murine type VII collagen distorts outcome in human skin graft mouse model for dystrophic epidermolysis bullosa.
Bremer J; Kramer D; Eichhorn DS; Gostyński A; Diercks GFH; Jonkman MF; van den Akker PC; Pasmooij AMG
Exp Dermatol; 2019 Oct; 28(10):1153-1155. PubMed ID: 30019435
[TBL] [Abstract][Full Text] [Related]
20. Translating the combination of gene therapy and tissue engineering for treating recessive dystrophic epidermolysis bullosa.
Dakiw Piaceski A; Larouche D; Ghani K; Bisson F; Cortez Ghio S; Larochelle S; Moulin VJ; Caruso M; Germain L
Eur Cell Mater; 2018 Feb; 35():73-86. PubMed ID: 29441510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
